A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus.

Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced positive top-line Phase II study results for its novel ...

Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2025 results , with sales up 9.4% year on year to $8.15 billion. The company expects the full year’s revenue to be around $35 billion, close to ...

IND filing and initial clinical data on first targeted Radio-DARPin therapy program, MP0712, expected in 2025; strategic partnership with Orano Med expanded from four to ten programs "Molecular ...

Close collaboration between researchers and clinicians at Mayo is what makes the steps of translation — from discovery to the ...

Patients and clinicians have welcomed the results of the ACT4 PLATO trial, which was the first clinical trial in the world to ...

Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 5.61%, which has investors questioning if this is right time to buy ...

After reviewing the Phase IV clinical trial report of Ademetionine Tablets, the Subject Expert Committee (SEC) functioning ...

A recent analysis reveals that ellipsoidal zone-retinal pigment epithelial thickness predicts future visual loss in ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today ...

Pasithea has announced the commencement of a Phase I/Ib open-label trial of PAS-004 for treating adults with ...